Genprex (GNPX)

• Market cap: $6.62M
• 1 day: -0.75%
• 5 days: -21.36%
• 1 month: -22.2%
• 3 months: -43.87%
• 6 months: -54.55%
• Year to date: -85.37%
• 1 year: -93.48%
• 5 years: -99.9%
• 10 years: -99.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Employees: 15